Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer. (Pubmed Abstract) Authors Dottino JA, Esselen KM, Costa R, Argetsinger S, Shahzad M, Ross-Degnan D, Wagner AK Abbreviation Value Health Publication Date 2024-06-11
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. (Pubmed Abstract) Authors Shahzad M, Naci H, Esselen KM, Dottino JA, Wagner AK Abbreviation J Pharm Policy Pract Volume 17 Issue 1 Publication Date 2024-06-04
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines. (Pubmed Abstract) Authors Soumerai SB, Shahzad M, Salzman C Abbreviation Am J Psychiatry Volume 181 Issue 3 Publication Date 2024-03-04
Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway. (Pubmed Abstract) Authors Shahzad M, Naci H, Wagner AK Abbreviation JAMA Publication Date 2023-01-27
Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval (Pubmed Abstract) (View Abstract) Authors Shahzad M, Naci H, Wagner AK. Volume 181 Issue 12 Publication Date 2021-10-18